168 related articles for article (PubMed ID: 29960059)
1. Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy.
Tanaka H; Yoshida S; Koga F; Toda K; Yoshimura R; Nakajima Y; Sugawara E; Akashi T; Waseda Y; Inoue M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1408-1416. PubMed ID: 29960059
[TBL] [Abstract][Full Text] [Related]
2. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
Patschan O; Sjödahl G; Chebil G; Lövgren K; Lauss M; Gudjonsson S; Kollberg P; Eriksson P; Aine M; Månsson W; Fernö M; Liedberg F; Höglund M
Eur Urol; 2015 Nov; 68(5):824-32; discussion 835-6. PubMed ID: 25770486
[TBL] [Abstract][Full Text] [Related]
3. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
[TBL] [Abstract][Full Text] [Related]
4. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
5. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
[TBL] [Abstract][Full Text] [Related]
6. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer.
Yoshida S; Koga F; Kobayashi S; Ishii C; Tanaka H; Tanaka H; Komai Y; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e21-7. PubMed ID: 22414281
[TBL] [Abstract][Full Text] [Related]
7. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
[TBL] [Abstract][Full Text] [Related]
8. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
[TBL] [Abstract][Full Text] [Related]
11. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
Hesswani C; Jackson CL; Marcq G; Hardy C; Kool R; Mansure JJ; Brimo F; Berman DM; Kassouf W
Eur Urol Open Sci; 2023 Nov; 57():22-29. PubMed ID: 38020525
[TBL] [Abstract][Full Text] [Related]
13. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer.
Koga F; Yoshida S; Tatokoro M; Kawakami S; Fujii Y; Kumagai J; Neckers L; Kihara K
PLoS One; 2011; 6(11):e27616. PubMed ID: 22102915
[TBL] [Abstract][Full Text] [Related]
14. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
Gray PJ; Fedewa SA; Shipley WU; Efstathiou JA; Lin CC; Zietman AL; Virgo KS
Eur Urol; 2013 May; 63(5):823-9. PubMed ID: 23200811
[TBL] [Abstract][Full Text] [Related]
15. Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Haque W; Verma V; Aghazadeh M; Darcourt J; Butler EB; Teh BS
Clin Genitourin Cancer; 2019 Oct; 17(5):e1069-e1079. PubMed ID: 31331865
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
Arcangeli G; Arcangeli S; Strigari L
Crit Rev Oncol Hematol; 2015 Apr; 94(1):105-15. PubMed ID: 25541350
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Weickhardt A; Foroudi F; Lawrentschuk N; Xie J; Sidhom M; Pal A; Grimison P; Zhang A; Ng S; Tang C; Hovey E; Chen C; Hruby G; Guminski A; McJannett M; Conduit C; Tran B; Davis ID; Hayne D
Eur Urol Oncol; 2024 Jun; 7(3):469-477. PubMed ID: 37806844
[TBL] [Abstract][Full Text] [Related]
18. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer.
Ritch CR; Balise R; Prakash NS; Alonzo D; Almengo K; Alameddine M; Venkatramani V; Punnen S; Parekh DJ; Gonzalgo ML
BJU Int; 2018 May; 121(5):745-751. PubMed ID: 29281848
[TBL] [Abstract][Full Text] [Related]
19. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy.
Iwai A; Koga F; Fujii Y; Masuda H; Saito K; Numao N; Sakura M; Kawakami S; Kihara K
Jpn J Clin Oncol; 2011 Dec; 41(12):1373-9. PubMed ID: 21994208
[TBL] [Abstract][Full Text] [Related]
20. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
